Participants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or clinically significant coagulopathy
Patients with uncontrolled coagulopathy or bleeding disorder are not eligible
Known bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy. Therapeutic anticoagulation is permitted, but patients must be on a stable dose.
Evidence or history of bleeding diathesis or coagulopathy
Participants with active bleeding disorder/coagulopathy
History of coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
History of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or clinically significant coagulopathy.
Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Bleeding disorder/coagulopathy
Uncontrolled coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
History of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathy
No coagulopathy or bleeding diathesis
Evidence of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or coagulopathy
History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation).
Uncontrolled coagulopathy or bleeding disorder
Known coagulopathy or bleeding diathesis; those on therapeutic anticoagulation or anti-platelet agent are permitted only after discussing with the study PI
Clinical evidence of bleeding diathesis or coagulopathy
Patients with uncontrolled coagulopathy or bleeding disorder
Evidence of bleeding diathesis or coagulopathy
Patients who have clinical history of coagulopathy, bleeding diathesis or thrombosis within the past year
Evidence of bleeding diathesis or coagulopathy within 3 months (eg, von Willebrand’s disease or hemophilia.
Uncontrolled coagulopathy
(Bevacizumab-related exclusion) Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Active coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence or history of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence or history of bleeding diathesis or coagulopathy
Inherited bleeding diathesis or coagulopathy with the risk of bleeding
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Patients with uncontrolled coagulopathy or bleeding disorder
uncorrectable coagulopathy
Active coagulopathy
Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation); any history of significant bleeding or thrombosis should be discussed with the study principal investigators (PIs)
REGORAFENIB EXCLUSION CRITERIA: Evidence or history of bleeding diathesis or coagulopathy
History of or genetic predisposition to a bleeding diathesis or coagulopathy
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nNo prior or current evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nNo prior or current evidence of coagulopathy or bleeding diathesis; therapeutic anti-coagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Patients who have clinical history of coagulopathy, bleeding diathesis or thrombosis within the past year
Evidence of clinically significant bleeding diathesis or underlying coagulopathy, non-healing wound
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding
Evidence of bleeding diathesis, coagulopathy as documented by an elevated PT, PTT or bleeding time
Clinical evidence of bleeding diathesis or coagulopathy
History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding
Evidence or history of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy (including clinically significant hemoptysis)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of active bleeding diathesis or coagulopathy\r\n* For the NSCLC expanded cohort only: history of “blood tinged” sputum allowed
No clinical evidence of hepatic failure (e.g. coagulopathy, ascites)
Patients with uncontrolled coagulopathy or bleeding disorder
Coagulopathy tests will be obtained within 2 weeks of enrollment
Haemorrhagic diathesis (i.e. haemophilia)
History of abnormal bleeding and coagulopathy
Bleeding or evidence or history of clinically significant bleeding diathesis or coagulopathy within the last 3 months
Clinically significant bleeding diathesis or coagulopathy
Use of full dose, therapeutic anti-coagulation or patients with uncontrolled coagulopathy or bleeding disorder
Uncontrolled coagulopathy
History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding
Evidence or history of bleeding diathesis or coagulopathy
Patients with a known coagulopathy or bleeding diathesis or require the use of systemic anticoagulant medication are not eligible
Disseminated intravascular coagulopathy with active bleeding or signs of thrombosis
Evidence of bleeding diathesis or coagulopathy
Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence or history of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Patient has a coagulopathy or bleeding disorder
Evidence or history of bleeding diathesis or coagulopathy
Patients must not have a known bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Contraindications to angiography and selective visceral catheterization such as bleeding diathesis or coagulopathy that is not correctable by usual therapy of hemostatic agents
No significant bleeding within the past 6 months; no bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
Evidence of bleeding diathesis or coagulopathy.
Evidence of bleeding diathesis or coagulopathy
Patients are excluded if they have evidence of bleeding diathesis or coagulopathy
Known coagulopathy or bleeding disorders are controlled
Evidence of bleeding diathesis or coagulopathy
Known bleeding disorder or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
Evidence or history of bleeding diathesis or coagulopathy.
Evidence or history of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy within the past 6 months
Evidence of bleeding diathesis or coagulopathy within 3 months
Patients with a history of hemoptysis, bleeding diathesis, known platelet disorder, or coagulopathy are not eligible
Known, existing uncontrolled coagulopathy
Evidence of bleeding diathesis or clinically significant coagulopathy
Evidence of prior or current coagulopathy or bleeding diathesis
Clinically-significant evidence of bleeding diathesis or coagulopathy as so judged by the treating physician
Evidence or history of bleeding diathesis or coagulopathy
Known, existing coagulopathy or receiving anticoagulants
Patients must have no evidence of bleeding diathesis or coagulopathy; patients must have no pathologic condition other than mesothelioma that carries a high risk of bleeding
Evidence or history of bleeding diathesis or coagulopathy
Pre-existing bleeding diathesis, coagulopathy or hemorrhage
Participants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding
Patients must have no known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe.
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or clinically significant coagulopathy
Evidence of bleeding diathesis or a clinically significant coagulopathy
Patients with an active, bleeding diathesis or significant coagulopathy
History of bleeding diathesis or coagulopathy. (Patients on stable anticoagulant therapy are eligible.)
Patient has a coagulopathy or bleeding disorder which is uncontrolled.
Evidence of bleeding diathesis or significant coagulopathy
Patients with uncontrolled coagulopathy or bleeding disorder
Evidence or history of bleeding diathesis or uncontrolled coagulopathy
Evidence or history of a bleeding diathesis or coagulopathy, including therapy-induced coagulopathy
Known, existing uncontrolled coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
History of coagulopathy or known thrombophilias
Concurrent use of anti-coagulant drugs (not including prophylactic doses), history of coagulopathy, or evidence of bleeding diathesis or coagulopathy
Presence of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
No known bleeding diathesis or coagulopathy
Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand disease or hemophilia)
Known, existing uncontrolled coagulopathy
History of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Known, existing uncontrolled coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
No history of clinical coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Coagulopathy or bleeding diathesis
No known coagulopathy
Patients must not have a known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the past
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy.
Nonreversible or uncorrectable coagulopathy. INR should not be >1.5,
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Concurrent anticoagulation will be permitted providing the patient is receiving a stable dose of anticoagulants before study entry; patients receiving anticoagulants will be eligible for this trial; evidence of clinically significant bleeding diathesis or underlying coagulopathy (e.g., INR > 1.5 without vitamin K antagonist therapy) will not be permitted
Evidence of clinically significant bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in absence of therapeutic anticoagulation)
Patients with uncontrolled coagulopathy or bleeding disorders
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Known bleeding disorder or coagulopathy
Clinically significant coagulopathy or bleeding disorder.
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of clinically significant bleeding diathesis or underlying coagulopathy (e.g. INR > 1.5 without vitamin K antagonist therapy), non-healing wound
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Patients must not have a bleeding diathesis, hereditary of acquired bleeding disorder or coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
History of bleeding diathesis or coagulopathy other than that due to anticoagulation therapy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy at the time of enrollment
Evidence or history of bleeding diathesis or coagulopathy
History of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Any evidence of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Pre-existing coagulopathy
Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders
Evidence or history of bleeding diathesis or coagulopathy
Uncorrected coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Known bleeding diathesis or coagulopathy
Subjects with uncorrected coagulopathy
Uncorrectable coagulopathy
Coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence or history of bleeding diathesis or coagulopathy
Patient has an uncorrectable coagulopathy
Uncontrollable coagulopathy
Coagulopathy
Uncontrolled coagulopathy or bleeding disorders
Known bleeding diathesis or coagulopathy
History of coagulopathy or bleeding disorders
Coagulopathy
Known inherited bleeding disorder or coagulopathy
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) within 4 weeks of first study dose
Severe coagulopathy or bleeding disorder
Uncorrectable coagulopathy
Uncorrectable coagulopathy
Known coagulopathy
Coagulopathy with platelets (Plt) < 10 k
Patient must not have a known bleeding diathesis or coagulopathy
Coagulopathy
Evidence of a coagulopathy